Condition: Cannabis Use Disorder · Cannabis Use Disorders · Cannabis Abuse · Sponsor: Anders Fink-Jensen, MD, DMSci
The HASHTAG Study is investigating whether the medicine semaglutide can help adults with cannabis use disorder (CUD) reduce their cannabis use. Participants will be randomly assigned to receive either semaglutide or a placebo. The first 50 participants will have functional brain scans (fMRI) to investigate how the brain responds to cannabis-related cues. The main outcome after 20 weeks is whether semaglutide reduces cannabis use compared to placebo. Changes in brain activity in response to cannabis cues will be explored as a secondary outcome.
This description comes directly from the study's public registry record.
Maria E Marstrand, MD · +4520896532 · maria.erlang.marstrand@regionh.dk
Anders Fink-Jensen, MD, DMSc · +4522755843 · anders.fink-jensen@regionh.dk
Always discuss trial participation with your own doctor first.
| Psychiatric Center Copenhagen, Frederiksberg Hospital | Frederiksberg, Denmark | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07523633